Journal of the American College of Cardiology
Audio Summaries

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Jun 10, 2026

The 2026 AHA/ACC/ADA/ASN Guideline aims to enhance the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome, which encompasses the interrelated conditions of metabolic risk factors, chronic kidney disease, and cardiovascular disease. This guideline replaces the 2013 version and is designed for clinicians treating patients with these interconnected health issues, providing updated evidence and recommendations based on a comprehensive literature review. The authors seek to create a dynamic resource that reflects the latest knowledge in managing this complex syndrome.

Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: 5-Year Follow-Up From the FAVOR III China Randomized Trial

Jun 10, 2026

The study aimed to assess the long-term effectiveness and safety of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) compared to angiography-guided PCI over a 5-year period. Results indicated that QFR guidance significantly reduced major adverse cardiac events, particularly myocardial infarctions and ischemia-driven revascularizations, with most benefits occurring within the first two years. However, all-cause mortality rates were similar between the two groups, suggesting that while QFR guidance improves outcomes, its advantages may diminish over time.

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology

Jun 9, 2026

The authors aim to establish a comprehensive framework for the primary prevention of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome by integrating predicted risk assessments with expected treatment benefits. They advocate for the use of the PREVENT equations to guide clinical decision-making regarding the initiation and intensification of therapies, emphasizing the importance of shared decision-making and effective risk communication. This scientific statement outlines the rationale, evidence, and practical guidance for implementing these recommendations to improve patient outcomes.